LOUVAIN-LA-NEUVE, BELGIUM and PETACH-TIKVA, ISRAEL--(Marketwire - August 13, 2008) - IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) the leading global provider of PET radiopharmaceuticals, and NST (NeuroSurvival Technologies Ltd.) the leading developer of agents targeting apoptosis (programmed cell death) for molecular imaging and therapy, today announced the signing of a collaboration agreement for radiolabeling and distributing APOSENSE® [18F]-ML-10, NST’s novel agent for molecular imaging of apoptosis, to sites participating in multi-center clinical trials of APOSENSE® [18F]-ML-10.
